NRX Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for central nervous system (CNS) disorders, specifically targeting suicidal depression, chronic pain, post-traumatic stress disorder (PTSD), and schizophrenia. The company's lead programs are built around its NMDA platform. Key assets include KETAFREE™ (a preservative-free formulation of ketamine for intravenous infusion), NRX-100 (preservative-free intravenous ketamine), and NRX-101 (an oral fixed-dose combination of D-cycloserine and lurasidone). NRx operates through its core biopharmaceutical development segment and its clinical services subsidiary, HOPE Therapeutics, which began generating clinical revenue in late 2025 through interventional psychiatry clinics.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Initiating commercial manufacturing of KETAFREE™ (preservative-free ketamine) at a level of 1 million doses per month to prepare for an anticipated FDA approval and market launch in Q3 2026.
Expected impact: Addresses the national sterile intravenous ketamine shortage and establishes NRx's first commercial pharmaceutical revenue stream.
Expanding the footprint of majority-owned subsidiary HOPE Therapeutics, Inc. from five active clinics to eight or more locations in Florida to deliver integrated interventional psychiatry care.
Expected impact: Drives clinical services revenue and provides a direct delivery network for neuroplastic therapies.
Advancing NRX-101 in combination with robotic-enabled Transcranial Magnetic Stimulation (TMS) into the MIND1 registrational trial for patients with depression and suicidality.
Expected impact: Could lead to accelerated FDA approval based on a single trial if clinical results are dramatically positive.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of a portfolio of assets targeting Human Endogenous Retroviruses (HERVs) implicated in Schizophrenia, Multiple Sclerosis, ALS, Autism, and Optic Neuritis through a Swiss court-supervised liquidation process.
Financial impact: Broadens the therapeutic pipeline with Phase 2 data, antibodies, cell lines, and patents, supported primarily through non-dilutive investment channels.
Strategic Partnerships
Deploying Emobot's AI-driven 'Depression Thermometer' (EMOCARE) across the HOPE Therapeutics clinic network to passively monitor patient emotional states via smartphones and prevent relapse.
Terms: Terms not publicly disclosed
Utilizing Osmind's real-world database of over 65,000 U.S. patients to support the FDA New Drug Application (NDA) review for NRX-100.
Terms: Terms not publicly disclosed